Improved in vivo experimental screening identifies an anabolic analog of 1,25 dihydroxyvitamin D3 with minimal bone resorption activity

Calvi, Laura M.¹

J Bone Miner Res. April 2020;35(4):621-622

Cited Works (3)

Year	Entry
2015	Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie S-AM. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. September 19-25, 2015;386(9999):1147.
2020	Plum LA, Zella J, Clagett‐Dame M, DeLuca HF. A new 1,25 dihydroxy vitamin D analog with strong bone anabolic activity in OVX rats with little or no bone resorptive activity. J Bone Miner Res. April 2020;35(4):623-630.
2005	Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ; PaTH Study Investigators. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. NEJM. August 11, 2005;353(6):555-565.